Common choices for the management of hyperprolactinaemia include switching the patient to a prolactin-sparing antipsychotic or additional use of D2 receptor agonist such as bromocriptine or cabergoline, however with increasing risk of adverse effects (Haddad and Wieck, 2004). This evidence concerns the gene PRL and hyperpituitarism.